Delisting risk
Cardiff Oncology (CRDF)
Develops onvansertib for first-line RAS-mutated metastatic colorectal cancer.
$1.03
Pre-market−0.02 (−1.90%)
At close$1.05(+1.94%)
Something off on this page? Send us feedback.
Next report
Nov 5, 2026
estimated · in 63 days
EPS estimate
−$0.15
Revenue estimate
$81.4K
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Feb '25May '25Jul '25Nov '25Feb '26May '26Aug '26Nov '26
Reported−$0.21−$0.20−$0.21−$0.17−$0.11−$0.18−$0.14Pending
Estimate−$0.26−$0.19−$0.19−$0.20−$0.18−$0.13−$0.12−$0.15
Surprise+19.2%−5.3%−10.5%+15.0%+38.9%−38.5%−17.0%—
RevenueReportedEstimate
Feb '25May '25Jul '25Nov '25Feb '26May '26Aug '26Nov '26
Reported$151.0K$109.0K$121.0K$120.0K$243.0K$41.0K$104.0KPending
Estimate$94.2K$89.3K$109.4K$103.5K$103.5K$88.6K$62.8K$81.4K
Surprise+60.3%+22.1%+10.6%+15.9%+134.8%−53.7%+65.7%—
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.15 | — | — |
| Aug 2026 | −$0.12 | −$0.14 | −17.0% |
| May 2026 | −$0.13 | −$0.18 | −38.5% |
| Feb 2026 | −$0.18 | −$0.11 | +38.9% |
| Nov 2025 | −$0.20 | −$0.17 | +15.0% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||
| Jul 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Feb 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Feb 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Feb 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Mar 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Mar 2016 | |||
| Nov 2015 | |||
| Aug 2015 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 5, 2026 | −$0.15 | — | — | $81.4K | — | — | — |
| Aug 11, 2026 | −$0.12 | −$0.14 | −17.0% | $62.8K | $104.0K | +65.7% | −5.7% |
| May 14, 2026 | −$0.13 | −$0.18 | −38.5% | $88.6K | $41.0K | −53.7% | −3.5% |
| Feb 24, 2026 | −$0.18 | −$0.11 | +38.9% | $103.5K | $243.0K | +134.8% | +12.4% |
| Nov 6, 2025 | −$0.20 | −$0.17 | +15.0% | $103.5K | $120.0K | +15.9% | −2.7% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||||||
| Jul 29, 2025 | |||||||
| May 8, 2025 | |||||||
| Feb 27, 2025 | |||||||
| Nov 7, 2024 | |||||||
| Aug 8, 2024 | |||||||
| May 2, 2024 | |||||||
| Feb 29, 2024 | |||||||
| Nov 2, 2023 | |||||||
| Aug 9, 2023 | |||||||
| May 4, 2023 | |||||||
| Mar 2, 2023 | |||||||
| Nov 3, 2022 | |||||||
| Aug 4, 2022 | |||||||
| May 5, 2022 | |||||||
| Feb 24, 2022 | |||||||
| Nov 4, 2021 | |||||||
| Aug 5, 2021 | |||||||
| May 6, 2021 | |||||||
| Feb 25, 2021 | |||||||
| Nov 5, 2020 | |||||||
| Aug 11, 2020 | |||||||
| May 7, 2020 | |||||||
| Feb 27, 2020 | |||||||
| Nov 7, 2019 | |||||||
| Aug 8, 2019 | |||||||
| May 7, 2019 | |||||||
| Mar 6, 2019 | |||||||
| Nov 7, 2018 | |||||||
| Aug 3, 2018 | |||||||
| May 8, 2018 | |||||||
| Feb 26, 2018 | |||||||
| Nov 9, 2017 | |||||||
| Aug 9, 2017 | |||||||
| May 10, 2017 | |||||||
| Mar 15, 2017 | |||||||
| Nov 9, 2016 | |||||||
| Aug 4, 2016 | |||||||
| May 10, 2016 | |||||||
| Mar 10, 2016 | |||||||
| Nov 9, 2015 | |||||||
| Aug 10, 2015 | |||||||